{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:53:53Z","timestamp":1790639633929,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL095685"],"award-info":[{"award-number":["R01 HL095685"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL149893"],"award-info":[{"award-number":["R01 HL149893"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910280"],"award-info":[{"award-number":["W81XWH1910280"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41375-021-01464-2","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:03:10Z","timestamp":1636120990000},"page":"746-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-2858","authenticated-orcid":false,"given":"Avik","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipmoy","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ferdous-Ur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Faughnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Foulks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-3627","authenticated-orcid":false,"given":"Chongzhi","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-4784","authenticated-orcid":false,"given":"Golam","family":"Mohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"1464_CR1","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"1464_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1464_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"1464_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1464_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"1464_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Eng J Med. 2005;352:1779\u201390.","journal-title":"N. Eng J Med"},{"key":"1464_CR7","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"1464_CR8","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"1464_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl J Med. 2013;369:2391\u2013405.","journal-title":"N. Engl J Med"},{"key":"1464_CR10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl J Med. 2013;369:2379\u201390.","journal-title":"N. Engl J Med"},{"key":"1464_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017;129:667\u201379.","journal-title":"Blood"},{"key":"1464_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl J Med. 2012;366:787\u201398.","journal-title":"N. Engl J Med"},{"key":"1464_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa R, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl J Med. 2012;366:799\u2013807.","journal-title":"N. Engl J Med"},{"key":"1464_CR14","doi-asserted-by":"crossref","unstructured":"Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4:e268.","DOI":"10.1038\/bcj.2014.84"},{"key":"1464_CR15","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u2013e324.","journal-title":"Lancet Haematol"},{"key":"1464_CR16","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv 2020;4:1792\u20131800.","journal-title":"Blood Adv"},{"key":"1464_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30:1701\u20137.","journal-title":"Leukemia"},{"key":"1464_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc2986","volume":"11","author":"MC Nawijn","year":"2011","unstructured":"Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11:23\u201334.","journal-title":"Nat Rev Cancer"},{"key":"1464_CR19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","volume":"95","author":"L Brault","year":"2010","unstructured":"Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004\u201315.","journal-title":"Haematologica"},{"key":"1464_CR20","doi-asserted-by":"publisher","first-page":"e1500221","DOI":"10.1126\/sciadv.1500221","volume":"8","author":"AS Green","year":"2015","unstructured":"Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv. 2015;8:e1500221.","journal-title":"Sci Adv"},{"key":"1464_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","volume":"3","author":"PJ Sung","year":"2019","unstructured":"Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 2019;3:1061\u201372.","journal-title":"Blood Adv"},{"key":"1464_CR22","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","volume":"114","author":"LS Chen","year":"2009","unstructured":"Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009;114:4150\u20137.","journal-title":"Blood"},{"key":"1464_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","volume":"123","author":"EK Keeton","year":"2014","unstructured":"Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123:905\u201313.","journal-title":"Blood"},{"key":"1464_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neo.2014.05.004","volume":"16","author":"JM Foulks","year":"2014","unstructured":"Foulks JM, Carpenter K, Luo B, Xu Y, Senina A, Nix R, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia 2014;16:403\u201312.","journal-title":"Neoplasia"},{"key":"1464_CR25","doi-asserted-by":"publisher","first-page":"8373","DOI":"10.1021\/acs.jmedchem.5b01275","volume":"58","author":"MT Burger","year":"2015","unstructured":"Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, et al. Identification of N-(4-((1R,3S,5S)\u22123-Amino-5-methylcyclohexyl)pyridin-3-yl)\u22126-(2,6-difluorophenyl)\u22125-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. J Med Chem 2015;58:8373\u201386.","journal-title":"J Med Chem"},{"key":"1464_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","volume":"118","author":"J Cortes","year":"2018","unstructured":"Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, et al. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018;118:1425\u201333.","journal-title":"Br J Cancer"},{"key":"1464_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer H, Cumano A, M\u00fcller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397\u2013409.","journal-title":"Cell"},{"key":"1464_CR28","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/stem.1711","volume":"32","author":"H Akada","year":"2014","unstructured":"Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells. 2014;32:1878\u201389.","journal-title":"Stem Cells"},{"key":"1464_CR29","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","volume":"24","author":"H Mikkers","year":"2004","unstructured":"Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004;24:6104\u201315.","journal-title":"Mol Cell Biol"},{"key":"1464_CR30","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","volume":"115","author":"H Akada","year":"2010","unstructured":"Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010;115:3589\u201397.","journal-title":"Blood"},{"key":"1464_CR31","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.7660125","volume":"269","author":"R K\u00fchn","year":"1995","unstructured":"K\u00fchn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269:1427\u20139.","journal-title":"Science"},{"key":"1464_CR32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/leu.2014.52","volume":"28","author":"H Akada","year":"2014","unstructured":"Akada H, Akada S, Hutchison RE, Mohi G. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice. Leukemia. 2014;28:1627\u201335.","journal-title":"Leukemia"},{"key":"1464_CR33","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010;115:2919\u201327.","journal-title":"Blood"},{"key":"1464_CR34","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1464_CR35","doi-asserted-by":"publisher","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","volume":"2","author":"L Yue","year":"2017","unstructured":"Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, et al. Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017;2:e90932.","journal-title":"JCI Insight"},{"key":"1464_CR36","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495\u2013503.","journal-title":"Blood"},{"key":"1464_CR37","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","volume":"121","author":"M Zingariello","year":"2013","unstructured":"Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D\u2019Amore E, et al. Characterization of the TGF-\u03b21 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood 2013;121:3345\u201363.","journal-title":"Blood"},{"key":"1464_CR38","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2016-12-757344","volume":"130","author":"A Dutta","year":"2017","unstructured":"Dutta A, Hutchison RE, Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2 V617F knockin mice by enhancing TGF-\u03b21 and Cxcl12 pathways. Blood 2017;130:920\u201332.","journal-title":"Blood"},{"key":"1464_CR39","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1158\/0008-5472.CAN-21-0590","volume":"81","author":"A Dutta","year":"2021","unstructured":"Dutta A, Nath D, Yang Y, Le BT, Mohi G. CDK6 is a therapeutic target in myelofibrosis. Cancer Res 2021;81:4332\u201345.","journal-title":"Cancer Res"},{"key":"1464_CR40","doi-asserted-by":"publisher","first-page":"e20190103","DOI":"10.1084\/jem.20190103","volume":"217","author":"N Frangogiannis","year":"2020","unstructured":"Frangogiannis N. Transforming growth factor-\u03b2 in tissue fibrosis. J Exp Med. 2020;217:e20190103.","journal-title":"J Exp Med"},{"key":"1464_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 2019;50:924\u201340.","journal-title":"Immunity"},{"key":"1464_CR42","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","volume":"3","author":"L Mazzacurati","year":"2019","unstructured":"Mazzacurati L, Collins RJ, Pandey G, Lambert-Showers QT, Amin NE, Zhang L, et al. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Adv. 2019;3:3503\u201314.","journal-title":"Blood Adv"},{"issue":"Jun","key":"1464_CR43","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1158\/1078-0432.CCR-20-4898","volume":"27","author":"RK Rampal","year":"2021","unstructured":"Rampal RK, Pinzon-Ortiz M, Somasundara AVH, Durham B, Koche R, Spitzer B, et al. Therapeutic efficacy of combined JAK1\/2, Pan-PIM, and CDK4\/6 inhibition in myeloproliferative neoplasms. Clin Cancer Res. 2021;27(Jun):3456\u201368.","journal-title":"Clin Cancer Res"},{"key":"1464_CR44","first-page":"183","volume":"21","author":"GY Liu","year":"2012","unstructured":"Liu GY, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;21:183\u2013203.","journal-title":"Cell"},{"key":"1464_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","volume":"571","author":"TL Aho","year":"2004","unstructured":"Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571:43\u201349.","journal-title":"FEBS Lett"},{"key":"1464_CR46","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","volume":"21","author":"QJ Wen","year":"2015","unstructured":"Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015;21:1473\u201380.","journal-title":"Nat Med"},{"key":"1464_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587:555\u201366.","journal-title":"Nature"},{"key":"1464_CR48","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","volume":"23","author":"A Tefferi","year":"2005","unstructured":"Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:8520\u201330.","journal-title":"J Clin Oncol"},{"key":"1464_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0348-9","volume":"9","author":"B Zhao","year":"2018","unstructured":"Zhao B, Liu L, Mao J, Zhang Z, Wang Q, Li Q. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis. Cell Death Dis 2018;9:307.","journal-title":"Cell Death Dis"},{"key":"1464_CR50","first-page":"586","volume":"8","author":"I Garrido-Laguna","year":"2020","unstructured":"Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, et al. A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors. J Clin Oncol. 2020;8:586.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01464-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T11:05:44Z","timestamp":1675854344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01464-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01464-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M. received research funding from Tolero Pharmaceutical Inc. J.M.F. and S.L.W. are employees and stakeholders of Sumitomo Dainippon Pharma Oncology, Inc. (formerly known as Tolero Pharmaceuticals, Inc). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}